Lorlatinib for previously treated ALK-positive advanced non-small-cell lung cancer

  • Technology appraisal guidance
  • TA628
  • Published: 
Download guidance (PDF)

2 Information about lorlatinib

Marketing authorisation indication

2.1 Lorlatinib (Lorviqua, Pfizer) as monotherapy is indicated for 'the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) whose disease has progressed after:

  • alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or

  • crizotinib and at least one other ALK TKI'.

Dosage in the marketing authorisation

2.2 The recommended dose is 100 mg lorlatinib taken orally once daily. Treatment with lorlatinib is recommended as long as the patient is benefitting from therapy without unacceptable toxicity.

Price

2.3 The list price of lorlatinib is £7,044.00 per 120-tablet pack of 25-mg tablets, and £5,283.00 per 30-tablet pack of 100-mg tablets (excluding VAT; BNF online accessed January 2020). The company has a commercial arrangement. This makes lorlatinib available to the NHS with a discount. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.